Citations to this article
Jonathan L. Golob, … , Adam S. Lauring, Anna S. Lok
Published April 6, 2021
Citation Information: JCI Insight. 2021;6(9):e149187. https://doi.org/10.1172/jci.insight.149187.
Citation Information: JCI Insight. 2021;6(9):e149187. https://doi.org/10.1172/jci.insight.149187.
Abstract
Roughly 1 year after the first case of COVID-19 was identified and less than 1 year after the sequencing of SARS-CoV-2, multiple SARS-CoV-2 vaccines with demonstrated safety and efficacy in phase III clinical trials are available. The most promising vaccines have targeted the surface glycoprotein (S-protein) of SARS-CoV-2 and achieved an approximate 85%–95% reduction in the risk of symptomatic COVID-19, while retaining excellent safety profiles and modest side effects in the phase III clinical trials. The mRNA, replication-incompetent viral vector, and protein subunit vaccine technologies have all been successfully employed. Some novel SARS-CoV-2 variants evade but do not appear to fully overcome the potent immunity induced by these vaccines. Emerging real-world effectiveness data add evidence for protection from severe COVID-19. This is an impressive first demonstration of the effectiveness of the mRNA vaccine and vector vaccine platforms. The success of SARS-CoV-2 vaccine development should be credited to open science, industry partnerships, harmonization of clinical trials, and the altruism of study participants. The manufacturing and distribution of the emergency use–authorized SARS-CoV-2 vaccines are ongoing challenges. What remains now is to ensure broad and equitable global vaccination against COVID-19.
Authors
Jonathan L. Golob, Njira Lugogo, Adam S. Lauring, Anna S. Lok
Citation information
Citations to this article (63)
| Title and authors | Publication | Year |
|---|---|---|
|
Seroprevalence against SARS-CoV-2 after booster vaccination in a prison in Alicante (Spain)
Montagud AC, Moragues R, Vicente-Alcalde N, Montagud E, Hurtado-Sánchez JA, Tuells J |
Frontiers in Public Health | 2025 |
|
Haemodialysis patients generate distinct antibody responses to the same antigen presented via different vaccine platforms.
Nadezhda Wall, Rachel Lamerton, Fiona Ashford, Marisol Perez-Toledo, Aleksandra Jasiulewicz, Gemma Banham, Maddy Newby, Sian Faustini, Alex Richter, Haresh Selvaskandan, Roseanne Billany, Sherna Adenwalla, Ian Henderson, Max Crispin, Matthew Graham-Brown, Lorraine Harper, Adam Cunningham |
Vaccines | 2024 |
|
Vitamin D Levels as a Marker of Severe SARS-CoV-2 Infection.
Athanassiou L, Kostoglou-Athanassiou I, Nikolakopoulou S, Konstantinou A, Mascha O, Siarkos E, Samaras C, Athanassiou P, Shoenfeld Y |
2024 | |
|
Structural and social factors affecting COVID-19 vaccine uptake among healthcare workers and older people in Uganda: A qualitative analysis.
Slivesteri S, Ssali A, Bahemuka UM, Nsubuga D, Muwanga M, Nsereko C, Ssemwanga E, Robert A, Seeley J, Elliott A, Ruzagira E |
2024 | |
|
The Limitations of a Hypothetical All-Variant COVID-19 Vaccine: A Simulation Study.
Kosinski RJ |
Human vaccines | 2024 |
|
Evolving Altruistic Attitudes towards Vaccination Post COVID-19 Pandemic: A Comparative Analysis across Age Groups.
Barbieri V, Wiedermann CJ, Lombardo S, Piccoliori G, Gärtner T, Engl A |
Human vaccines | 2024 |
|
The societal impact of Open Science: a scoping review.
Cole NL, Kormann E, Klebel T, Apartis S, Ross-Hellauer T |
Royal Society Open Science | 2024 |
|
Epitopes screening and vaccine molecular design of PEDV S protein based on immunoinformatics.
Li S, Bai X, Wang C |
Scientific reports | 2024 |
|
Assessment of immune responses to a Comirnaty® booster following CoronaVac® vaccination in healthcare workers
Bochnia-Bueno L, Coelho GM, Cataneo AH, Zanluca C, Ferreira LH, Cavalcanti LP, Clementino MA, Yaochite JN, dos Santos HG, Nogueira MB, Duarte dos Santos CN, Raboni SM |
Memórias do Instituto Oswaldo Cruz | 2024 |
|
A potential allosteric inhibitor of SARS-CoV-2 main protease (Mpro) identified through metastable state analysis
Fatima A, Geethakumari AM, Ahmed WS, Biswas KH |
Frontiers in Molecular Biosciences | 2024 |
|
Developer and Partnership Differences in COVID-19 and Other Infections: Insights from DNA Vaccines
Okuyama R |
Journal of Market Access & Health Policy | 2024 |
|
Rethinking next-generation vaccines for coronaviruses, influenzaviruses, and other respiratory viruses
Morens DM, Taubenberger JK, Fauci AS |
Cell Host & Microbe | 2023 |
|
The OM-85 bacterial lysate: a new tool against SARS-CoV-2?
Pivniouk V, Vercelli D |
Multidisciplinary Respiratory Medicine | 2023 |
|
Age-Related Associations of Altruism with Attitudes towards COVID-19 and Vaccination: A Representative Survey in the North of Italy
Barbieri V, Wiedermann CJ, Lombardo S, Plagg B, Piccoliori G, Gärtner T, Engl A |
Behavioral Science | 2023 |
|
Novel Inhibitory Role of Fenofibric Acid by Targeting Cryptic Site on the RBD of SARS-CoV-2
Huang J, Chan KC, Zhou R |
Biomolecules | 2023 |
|
IgA antibody dynamics in healthcare workers after CoronaVac® vaccination and heterologous Comirnaty® booster dose.
Bochnia-Bueno L, Ferreira LH, Genelhoud G, Nogueira MB, Raboni SM |
Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] | 2023 |
|
Epitopes screening and vaccine molecular design of SADS-CoV based on immunoinformatics
Li S, Chen Y |
Frontiers in Veterinary Science | 2023 |
|
The Role of Folic Acid in SARS-CoV-2 Infection: An Intriguing Linkage under Investigation
Karakousis ND, Gourgoulianis KI, Kotsiou OS |
Journal of Personalized Medicine | 2023 |
|
Cutaneous Sarcoidosis-like Eruption Following Second Dose of Moderna mRNA-1273 Vaccine: Case or Relationship?
Cazzato G, Ambrogio F, Foti C, Capuzzolo M, Trilli I, Casatta N, Lupo C, Carrieri M, Daini D, Colagrande A, Maiorano E, Ingravallo G |
Diagnostics | 2023 |
|
Have Diagnostics, Therapies, and Vaccines Made the Difference in the Pandemic Evolution of COVID-19 in Comparison with “Spanish Flu”?
Lista F, Peragallo MS, Biselli R, De Santis R, Mariotti S, Nisini R, D\u2019Amelio R |
Pathogens | 2023 |
|
Novel receptor, mutation, vaccine, and establishment of coping mode for SARS-CoV-2: current status and future
Zeng Z, Geng X, Wen X, Chen Y, Zhu Y, Dong Z, Hao L, Wang T, Yang J, Zhang R, Zheng K, Sun Z, Zhang Y |
Frontiers in microbiology | 2023 |
|
Aerosol Inhalation of Chimpanzee Adenovirus Vectors (ChAd68) Expressing Ancestral or Omicron BA.1 Stabilized Pre–Fusion Spike Glycoproteins Protects Non–Human Primates against SARS-CoV-2 Infection
Wang S, Qin M, Xu L, Mu T, Zhao P, Sun B, Wu Y, Song L, Wu H, Wang W, Liu X, Li Y, Yang F, Xu K, He Z, Klein M, Wu K |
Human vaccines | 2023 |
|
Integration of Omics Data and Network Models to Unveil Negative Aspects of SARS-CoV-2, from Pathogenic Mechanisms to Drug Repurposing
Bernardo L, Lomagno A, Mauri PL, Di Silvestre D |
Biology | 2023 |
|
The Impact of SARS-CoV-2 Immune Status and Societal Restrictions in Controlling COVID-19 across the World.
Stroo J, Lepolder M, Murk JL, Rijkers GT |
Human vaccines | 2023 |
|
Impact on the German asymptomatic screening strategy based on actual user data from SARS-CoV-2 test centers
Grohmann M, Grosch J, Conrady B, Schomakers L, Witte AK |
Scientific Reports | 2023 |
|
Factors Related to Low COVID-19 Vaccination Rate in Pregnant and Postpartum Women with and without COVID-19
Beser DM, Hendem DU, Oluklu D, Turgut E, Hancerliogullari N, Ayhan SG, Tekin OM, Sahin D |
2023 | |
|
SARS-CoV-2 vaccination and multiple sclerosis: a large multicentric study on relapse risk after the third booster dose.
Di Filippo M, Ferraro D, Ragonese P, Prosperini L, Maniscalco GT, Gallo A, Cavalla P, Lorefice L, Nociti V, Di Sabatino E, Clerico M, Guaschino C, Radaelli M, Fantozzi R, Buttari F, Laroni A, Gajofatto A, Calabrese M, Malucchi S, Paolicelli D, De Luca G, Tomassini V, Lanzillo R, Moccia M, Solaro C, Cocco E, Gasperini C, Tortorella C |
Journal of Neurology | 2023 |
|
Clinical development of antivirals against SARS-CoV-2 and its variants
Lan Q, Yan Y, Zhang G, Xia S, Zhou J, Lu L, Jiang S |
2023 | |
|
Untoward immune effects of modern medication
Chen D |
Journal of Biomedical Research | 2023 |
|
On the Origin of Neutrophil Extracellular Traps in COVID-19
M Pastorek, M Dúbrava, P Celec |
Frontiers in immunology | 2022 |
|
Insights into the immune responses of SARS-CoV-2 in relation to COVID-19 vaccines
H Park, M Park, J Seok, J You, J Kim, J Kim, M Park |
The Journal of Microbiology | 2022 |
|
Dynamic of humoral response to SARS-CoV-2 anti-Nucleocapsid and Spike proteins after CoronaVac vaccination
L Bochnia-Bueno, SM Almeida, SM Raboni, D Adamoski, LL Amadeu, S Carstensen, MB Nogueira |
Diagnostic Microbiology and Infectious Disease | 2022 |
|
Identification of potentially anti-COVID-19 active drugs using the connectivity MAP
R Bonnet, L Mariault, J Peyron, A Kumar |
PloS one | 2022 |
|
Accelerating research and development of new vaccines against tuberculosis: a global roadmap
F Cobelens, R Suri, M Helinski, M Makanga, A Weinberg, B Schaffmeister, F Deege, M Hatherill |
The Lancet Infectious Diseases | 2022 |
|
Ultrastructural examination of lung “cryobiopsies” from a series of fatal COVID-19 cases hardly revealed infected cells
K Cortese, G Holland, L Möller, M Gagliani, E Barisione, L Ball, P Pelosi, F Grillo, L Mastracci, R Fiocca, M Laue |
Virchows Archiv | 2022 |
|
Antibody responses after two doses of SARS-CoV-2 mRNA-1273 vaccine in an individual with history of COVID-19 re-infection
M Inada, M Ishikane, M Terada, A Matsunaga, K Maeda, N Iwamoto, M Ujiie, S Kutsuna, S Morioka, Y Ishizaka, H Mitsuya, N Ohmagari |
International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases | 2022 |
|
COVID-19 mRNA Vaccine in Patients With Lymphoid Malignancy or Anti-CD20 Antibody Therapy: A Systematic Review and Meta-Analysis.
Ito Y, Honda A, Kurokawa M |
Clinical Lymphoma, Myeloma & Leukemia | 2022 |
|
Acculturation, trust to health care system, and attitudes to COVID-19 vaccination: A comparative study between Polish immigrants in Norway, Polish in Poland, and Norwegians in Norway.
Lajunen T, Wróbel B |
2022 | |
|
Real-world studies: bridging the gap between trial-assessed efficacy and routine care.
Chen D |
Journal of Biomedical Research | 2022 |
|
Borneol Ester Derivatives as Entry Inhibitors of a Wide Spectrum of SARS-CoV-2 Viruses.
Yarovaya OI, Shcherbakov DN, Borisevich SS, Sokolova AS, Gureev MA, Khamitov EM, Rudometova NB, Zybkina AV, Mordvinova ED, Zaykovskaya AV, Rogachev AD, Pyankov OV, Maksyutov RA, Salakhutdinov NF |
Viruses | 2022 |
|
Immunity after COVID-19 Recovery and Vaccination: Similarities and Differences
Kamińska D, Dęborska-Materkowska D, Kościelska-Kasprzak K, Mazanowska O, Remiorz A, Poznański P, Durlik M, Krajewska M |
Human vaccines | 2022 |
|
Synthetic chromosomes, genomes, viruses, and cells.
Venter JC, Glass JI, Hutchison CA 3rd, Vashee S |
Cell | 2022 |
|
Is it safe and effective to administer COVID-19 vaccines during pregnancy? A systematic review and meta-analysis
Hameed I, Khan MO, Nusrat K, Mahmood S, Nashit M, Malik S, Siddiqui OM, Samad SA, Marsia S, Usman MS, Siddiqi TJ |
American journal of infection control | 2022 |
|
A universal SARS‐CoV DNA vaccine inducing highly cross‐reactive neutralizing antibodies and T cells
Appelberg S, Ahlén G, Yan J, Nikouyan N, Weber S, Larsson O, Höglund U, Aleman S, Weber F, Perlhamre E, Apro J, Gidlund E, Tuvesson O, Salati S, Cadossi M, Tegel H, Hober S, Frelin L, Mirazimi A, Sällberg M |
EMBO Molecular Medicine | 2022 |
|
SARS-CoV-2 infections elicit higher levels of original antigenic sin antibodies compared with SARS-CoV-2 mRNA vaccinations
Anderson EM, Li SH, Awofolaju M, Eilola T, Goodwin E, Bolton MJ, Gouma S, Manzoni TB, Hicks P, Goel RR, Painter MM, Apostolidis SA, Mathew D, Dunbar D, Fiore D, Brock A, Weaver J, Millar JS, DerOhannessian S, Greenplate AR, Frank I, Rader DJ, Wherry EJ, Bates P, Hensley SE |
Cell Reports | 2022 |
|
A Comprehensive Review on the Current Vaccines and Their Efficacies to Combat SARS-CoV-2 Variants.
Rabaan AA, Mutair AA, Hajissa K, Alfaraj AH, Al-Jishi JM, Alhajri M, Alwarthan S, Alsuliman SA, Al-Najjar AH, Al Zaydani IA, Al-Absi GH, Alshaikh SA, Alkathlan MS, Almuthree SA, Alawfi A, Alshengeti A, Almubarak FZ, Qashgari MS, Abdalla ANK, Alhumaid S |
Human vaccines | 2022 |
|
Assessment of SARS-CoV-2 vaccination status in SARS-COV-2 infected patients admitted in Dr Ruth K.M. Pfau, Civil Hospital Karachi.
Rasheed T, Ali FS, Zuberi BF, Sadaf R |
Pakistan Journal of Medical Sciences | 2022 |
|
A mathematical prediction model of infectious diseases considering vaccine and temperature, and its prediction in Hong Kong
Ai H, Wang Q, Liu W |
Heliyon | 2022 |
|
Therapies Targeted at Non-Coding RNAs in Prevention and Limitation of Myocardial Infarction and Subsequent Cardiac Remodeling—Current Experience and Perspectives
M Kowara, S Borodzicz-Jazdzyk, K Rybak, M Kubik, A Cudnoch-Jedrzejewska |
International journal of molecular sciences | 2021 |
|
Immune-Mediated Disease Flares or New-Onset Disease in 27 Subjects Following mRNA/DNA SARS-CoV-2 Vaccination
A Watad, GD Marco, H Mahajna, A Druyan, M Eltity, N Hijazi, A Haddad, M Elias, D Zisman, ME Naffaa, M Brodavka, Y Cohen, A Abu-Much, MA Elhija, C Bridgewood, P Langevitz, J McLorinan, NL Bragazzi, H Marzo-Ortega, M Lidar, C Calabrese, L Calabrese, E Vital, Y Shoenfeld, H Amital, D McGonagle |
Human vaccines | 2021 |
|
Fusion Protein of Rotavirus VP6 and SARS-CoV-2 Receptor Binding Domain Induces T Cell Responses
K Tamminen, S Heinimäki, S Gröhn, V Blazevic |
Human vaccines | 2021 |
|
Severe Acute Respiratory Syndrome Coronavirus 2: Manifestations of Disease and Approaches to Treatment and Prevention in Humans
ME Watson, K Inagaki, JB Weinberg |
Comparative medicine | 2021 |
|
Actions and attitudes on the immunized patients against SARS-CoV-2
P Ramos, A García-Botella, A García-Lledó, J Gómez-Pavón, J del Castillo, T Hernández-Sampelayo, M Martín-Delgado, F Sánchez, M Martínez-Sellés, J García, S Guillén, F Rodríguez-Artalejo, J Ruiz-Galiana, R Cantón, E Bouza |
REV ESP QUIM | 2021 |
|
Tenofovir, Another Inexpensive, Well-Known and Widely Available Old Drug Repurposed for SARS-COV-2 Infection
I Zanella, D Zizioli, F Castelli, E Quiros-Roldan |
Pharmaceuticals (Basel, Switzerland) | 2021 |
|
A Comprehensive Review of COVID-19 Virology, Vaccines, Variants, and Therapeutics
L Forchette, W Sebastian, T Liu |
2021 | |
|
Evolution, Mode of Transmission, and Mutational Landscape of Newly Emerging SARS-CoV-2 Variants
C Chakraborty, AR Sharma, M Bhattacharya, G Agoramoorthy, SS Lee, SP Goff |
mBio | 2021 |
|
Prenatal maternal COVID-19 vaccination and pregnancy outcomes
T Wainstock, I Yoles, R Sergienko, E Sheiner |
Vaccine | 2021 |
|
B.1.617.2 enters and fuses lung cells with increased efficiency and evades antibodies induced by infection and vaccination
P Arora, A Sidarovich, N Krüger, A Kempf, I Nehlmeier, L Graichen, AS Moldenhauer, MS Winkler, S Schulz, HM Jäck, MV Stankov, GM Behrens, S Pöhlmann, M Hoffmann |
Cell Reports | 2021 |
|
The COVID-19 pandemic: some thoughts on integrity in research and communication
D Morens, Z Hammatt |
Forensic Sciences Research | 2021 |
|
A transformed global enterprise for an HIV vaccine
R Tatoud, W Snow, J Esparza |
Journal of the International AIDS Society | 2021 |
|
Perspectives on passive antibody therapy and peptide-based vaccines against emerging pathogens like SARS-CoV-2
M Palma |
GERMS | 2021 |
|
Attitudes toward vaccination in patients with multiple sclerosis: A report from Iran
F Ghadiri, MA Sahraian, R Saeedi, AN Moghadasi |
Multiple Sclerosis and Related Disorders | 2021 |
|
HIV vaccines beyond COVID‐19: merits of trust
JG Kublin |
Journal of the International AIDS Society | 2021 |
